자가면역질환 치료제 시장(2026-2030년)

The global autoimmune drugs market is forecasted to grow by USD 38227.2 mn during 2025-2030, accelerating at a CAGR of 6.9% during the forecast period. The report on the global autoimmune drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of autoimmune disorders and increased diagnostic capabilities, transition toward precision-targeted biologics and advanced monoclonal antibodies, proliferation of biosimilars and favorable regulatory frameworks.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global autoimmune drugs market is segmented as below:

By Therapy Area

• Rheumatoid arthritis
• Multiple sclerosis
• Psoriasis
• Inflammatory bowel disease
• Others

By Distribution Channel

• Hospital
• Pharmacy
• Retail pharmacy
• Online

By Route Of Administration

• Injectable
• Oral
• Topical

By Drug Class

• Biologics and biosimilars
• Small molecules and JAK inhibitors
• Immunosuppressants
• Corticosteroids and NSAIDs
• Interferons

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the integration of ai and ml in drug discovery as one of the prime reasons driving the global autoimmune drugs market growth during the next few years. Also, expansion of subcutaneous delivery systems and self-administered formulations and accelerated penetration of biosimilars across emerging and developed geographies will lead to sizable demand in the market.

The report on the global autoimmune drugs market covers the following areas:

• Global autoimmune drugs market sizing
• Global autoimmune drugs market forecast
• Global autoimmune drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global autoimmune drugs market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Co Inc., Bayer AG, Biogen Inc., Bristol Myers Squibb Co., Celltrion Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Incyte Corp., Johnson and Johnson, LEO Pharma AS, Merck KGaA, Novartis AG, Organon and Co., Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Takeda Pharmaceutical Ltd., UCB SA. Also, the global autoimmune drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Therapy Area
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Autoimmune Drugs Market 2020 - 2024
  • Historic Market Size - Data Table on Global Autoimmune Drugs Market 2020 - 2024 ($ million)
• 5.2 Therapy Area segment analysis 2020 - 2024
  • Historic Market Size - Therapy Area Segment 2020 - 2024 ($ million)
• 5.3 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.4 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
• 5.5 Drug Class segment analysis 2020 - 2024
  • Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
• 5.6 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.7 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global autoimmune drugs market
• 6.2 Impact of geopolitical conflicts on global autoimmune drugs market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Therapy Area

• 8.1 Market segments
• 8.2 Comparison by Therapy Area
• 8.3 Rheumatoid arthritis - Market size and forecast 2025-2030
• 8.4 Multiple sclerosis - Market size and forecast 2025-2030
• 8.5 Psoriasis - Market size and forecast 2025-2030
• 8.6 Inflammatory bowel disease - Market size and forecast 2025-2030
• 8.7 Others - Market size and forecast 2025-2030
• 8.8 Market opportunity by Therapy Area
  • Market opportunity by Therapy Area ($ million)

9 Market Segmentation by Distribution Channel

• 9.1 Market segments
• 9.2 Comparison by Distribution Channel
• 9.3 Hospital - Market size and forecast 2025-2030
• 9.4 Pharmacy - Market size and forecast 2025-2030
• 9.5 Retail pharmacy - Market size and forecast 2025-2030
• 9.6 Online - Market size and forecast 2025-2030
• 9.7 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

10 Market Segmentation by Route of Administration

• 10.1 Market segments
• 10.2 Comparison by Route of Administration
• 10.3 Injectable - Market size and forecast 2025-2030
• 10.4 Oral - Market size and forecast 2025-2030
• 10.5 Topical - Market size and forecast 2025-2030
• 10.6 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

11 Market Segmentation by Drug Class

• 11.1 Market segments
• 11.2 Comparison by Drug Class
• 11.3 Biologics and biosimilars - Market size and forecast 2025-2030
• 11.4 Small molecules and JAK inhibitors - Market size and forecast 2025-2030
• 11.5 Immunosuppressants - Market size and forecast 2025-2030
• 11.6 Corticosteroids and NSAIDs - Market size and forecast 2025-2030
• 11.7 Interferons - Market size and forecast 2025-2030
• 11.8 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)

12 Customer Landscape

• 12.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

13 Geographic Landscape

• 13.1 Geographic segmentation
• 13.2 Geographic comparison
• 13.3 North America - Market size and forecast 2025-2030
  • 13.3.1 US - Market size and forecast 2025-2030
  • 13.3.2 Canada - Market size and forecast 2025-2030
  • 13.3.3 Mexico - Market size and forecast 2025-2030
• 13.4 Europe - Market size and forecast 2025-2030
  • 13.4.1 Germany - Market size and forecast 2025-2030
  • 13.4.2 UK - Market size and forecast 2025-2030
  • 13.4.3 France - Market size and forecast 2025-2030
  • 13.4.4 Italy - Market size and forecast 2025-2030
  • 13.4.5 Spain - Market size and forecast 2025-2030
  • 13.4.6 The Netherlands - Market size and forecast 2025-2030
• 13.5 Asia - Market size and forecast 2025-2030
  • 13.5.1 China - Market size and forecast 2025-2030
  • 13.5.2 India - Market size and forecast 2025-2030
  • 13.5.3 Japan - Market size and forecast 2025-2030
  • 13.5.4 South Korea - Market size and forecast 2025-2030
  • 13.5.5 Indonesia - Market size and forecast 2025-2030
  • 13.5.6 Thailand - Market size and forecast 2025-2030
• 13.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 13.6.1 Brazil - Market size and forecast 2025-2030
  • 13.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 13.6.3 UAE - Market size and forecast 2025-2030
  • 13.6.4 Turkey - Market size and forecast 2025-2030
  • 13.6.5 Argentina - Market size and forecast 2025-2030
  • 13.6.6 Colombia - Market size and forecast 2025-2030
  • 13.6.7 South Africa - Market size and forecast 2025-2030
  • 13.6.8 Israel - Market size and forecast 2025-2030
• 13.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

14 Drivers, Challenges, and Opportunity

• 14.1 Market drivers
  • Rising prevalence of autoimmune disorders and increased diagnostic capabilities
  • Transition toward precision-targeted biologics and advanced monoclonal antibodies
  • Proliferation of biosimilars and favorable regulatory frameworks
• 14.2 Market challenges
  • Exorbitant treatment costs and severe reimbursement constraints
  • Complex manufacturing requirements and vulnerable global supply chains
  • Stringent regulatory hurdles and patent cliff pressures
• 14.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 14.4 Market opportunities
  • Integration of AI and ML in drug discovery
  • Expansion of subcutaneous delivery systems and self-administered formulations
  • Accelerated penetration of biosimilars across emerging and developed geographies

15 Competitive Landscape

• 15.1 Overview
• 15.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 15.3 Landscape disruption
  • Overview on factors of disruption
• 15.4 Industry risks
  • Impact of key risks on business

16 Competitive Analysis

• 16.1 Companies profiled
  • Companies covered
• 16.2 Company ranking index
  • Company ranking index
• 16.3 Market positioning of companies
  • Matrix on companies position and classification
• 16.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Segment focus
  • SWOT
• 16.5 Amgen Inc.
  • Amgen Inc. - Overview
  • Amgen Inc. - Product / Service
  • Amgen Inc. - Key news
  • Amgen Inc. - Key offerings
  • SWOT
• 16.6 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Business segments
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Segment focus
  • SWOT
• 16.7 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 16.8 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 16.9 Eli Lilly and Co.
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key news
  • Eli Lilly and Co. - Key offerings
  • SWOT
• 16.10 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 16.11 Gilead Sciences Inc.
  • Gilead Sciences Inc. - Overview
  • Gilead Sciences Inc. - Business segments
  • Gilead Sciences Inc. - Key news
  • Gilead Sciences Inc. - Key offerings
  • Gilead Sciences Inc. - Segment focus
  • SWOT
• 16.12 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT
• 16.13 Johnson and Johnson
  • Johnson and Johnson - Overview
  • Johnson and Johnson - Business segments
  • Johnson and Johnson - Key news
  • Johnson and Johnson - Key offerings
  • Johnson and Johnson - Segment focus
  • SWOT
• 16.14 Merck KGaA
  • Merck KGaA - Overview
  • Merck KGaA - Business segments
  • Merck KGaA - Key news
  • Merck KGaA - Key offerings
  • Merck KGaA - Segment focus
  • SWOT
• 16.15 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 16.16 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 16.17 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 16.18 Takeda Pharmaceutical Ltd.
  • Takeda Pharmaceutical Ltd. - Overview
  • Takeda Pharmaceutical Ltd. - Business segments
  • Takeda Pharmaceutical Ltd. - Key news
  • Takeda Pharmaceutical Ltd. - Key offerings
  • Takeda Pharmaceutical Ltd. - Segment focus
  • SWOT

17 Appendix

• 17.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 17.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 17.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 17.4 Research methodology
  • Research methodology
• 17.5 Data procurement
  • Information sources
• 17.6 Data validation
  • Data validation
• 17.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 17.8 Data synthesis
  • Data synthesis
• 17.9 360 degree market analysis
  • 360 degree market analysis
• 17.10 List of abbreviations
  • List of abbreviations